{"entity":{"id":"louis-staudt","kind":"person","name":"Louis M. Staudt","aka":[],"tldr":"Louis Staudt defined the molecular subtypes of large B-cell lymphoma that guide targeted therapy.","summary":"Louis M. Staudt is Director of the Center for Cancer Genomics and Chief of the Lymphoid Malignancies Branch at the National Cancer Institute. He is known for defining the molecular subtypes of diffuse large B-cell lymphoma that guide targeted therapy, discovering the germinal-centre and activated B-cell subtypes and the chronic active B-cell receptor signalling that made BTK inhibitors work in lymphoma. His selected papers report distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, and review the genetics and pathogenesis of the disease. He now directs NCI's cancer genomics centre.","asOf":"2026-09-08","links":[{"label":"NCI CCR profile","url":"https://ccr.cancer.gov/staff-directory/louis-m-staudt"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Staudt%20LM%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":["rna-seq"],"targets":["btk"],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Center for Cancer Genomics; Chief, Lymphoid Malignancies Branch","institutionId":"nci","specialisms":["Lymphoma genomics","Molecular subtypes of DLBCL","BTK signalling"],"profiles":[{"label":"NCI CCR profile","url":"https://ccr.cancer.gov/staff-directory/louis-m-staudt"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Staudt%20LM%5BAuthor%5D"}],"papers":[{"title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","journal":"Nature","year":2000,"url":"https://doi.org/10.1038/35000501","doi":"10.1038/35000501"},{"title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","journal":"New England Journal of Medicine","year":2018,"url":"https://doi.org/10.1056/NEJMoa1801445","doi":"10.1056/NEJMoa1801445"}]},"route":"/people/louis-staudt/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"technology":[{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/"}],"target":[{"id":"btk","kind":"target","name":"BTK (Bruton tyrosine kinase)","route":"/targets/btk/"}],"institution":[{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"},{"id":"nci-ccr","kind":"institution","name":"NCI Center for Cancer Research (intramural programme)","route":"/institutions/nci-ccr/"}],"paper":[{"id":"paper-wright-lymphgen-genetic-subtypes-dlbcl-cancer-cell-2020","kind":"paper","name":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","route":"/key-papers/paper-wright-lymphgen-genetic-subtypes-dlbcl-cancer-cell-2020/"},{"id":"paper-schmitz-genetics-pathogenesis-dlbcl-nejm-2018","kind":"paper","name":"Genetics and pathogenesis of diffuse large B-cell lymphoma","route":"/key-papers/paper-schmitz-genetics-pathogenesis-dlbcl-nejm-2018/"},{"id":"paper-rosenwald-molecular-profiling-dlbcl-nejm-2002","kind":"paper","name":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","route":"/key-papers/paper-rosenwald-molecular-profiling-dlbcl-nejm-2002/"}],"roadmap":[{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"}]}}